Clinical trials: Epirubicin
Breast Cancer
Neoadjuvant Treatment of Breast Cancer
Observational investigation of participants who are given neoadjuvant treatment for invasive breast cancer. The scope of the study is to collect information on standardized treatment results, to explore the causes of dose…
- Trial name
- NCT05131893
- Testing
- Tamoxifen, Goserelin, Letrozole 2.5Mg Tab
- Where
- Hungary
- Volunteers
- 300 people
- Sponsor
- National Institute of Oncology, Hungary
Bladder Cancer
Effectiveness of an Immediate Postoperative Intravesical Instillation With Either Gemcitabine or Epirubicin in Patients With Urinary Bladder Cancer (Gemcitabine Epirubicin Normal SAline)
The natural history of non-muscle-invasive bladder cancer is characterised by recurrence and progression. We compare the effectiveness of gemcitabine hydrochloride and epirubicin hydrochloride, in combination with continuous…
- Trial name
- GENSA (NCT04947059)
- Testing
- Gemcitabine Hydrochloride combined with continuous saline irrigation, Epirubicin Hydrochloride combined with continuous saline irrigation
- Where
- Greece
- Volunteers
- 180 people
- Sponsor
- University of Thessaly
Breast Cancer
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with…
- Trial name
- NCT06112379
- Testing
- Dato-DXd, Durvalumab, Pembrolizumab
- Where
- 283 sites in United States, Australia and 24 more
- Volunteers
- 1,902 people
- Sponsor
- AstraZeneca
Breast Cancer
Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients
A multicenter, prospective, open, randomized cohort, non controlled phase II clinical study to evaluate the effectiveness and safety of Darxil combined with Exemestane+goserelin neoadjuvant endocrine therapy in HR positive and…
- Trial name
- NCT06009627
- Testing
- dalpiciclib、Exemestane、Gosserine, Docetaxel for injection、Epirubicin hydrochloride for injection、Cyclophosphamide for injection
- Where
- China
- Volunteers
- 119 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer
Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC)
Triple-negative breast cancer (TNBC) is a term applied to breast cancer cases that have <1% expression of the estrogen receptor (ER) and the progesterone receptor (PR) and do not over express HER2.
- Trial name
- OTT15-04 (NCT02688803)
- Testing
- Dose dense AC-P, Dose dense AC, FEC-D
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Ottawa Hospital Research Institute
Breast Cancer
Trial of Neoadjuvant Endostar, Docetaxel and Epirubicin for Patients With Breast Cancer
This study was designed to determine the efficacy and safety of neoadjuvant docetaxel and epirubicin (DE) with or without human recombinant endostatin (endostar) for breast cancer patients.
- Trial name
- CBCRT01 (NCT01479036)
- Testing
- docetaxel and epirubicin, docetaxel and epirubicin plus endostatin
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Xijing Hospital
Breast Cancer
Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer
This study proposes to prove that the efficacy of adjuvant endocrine therapy for the premenopausal HR positive breast cancer patients is non-inferiority to adjuvant chemotherapy assessed by ultrasound response rate.
- Trial name
- NCT02535221
- Testing
- Goserelin+TAM+AI, Epirubicin+CTX+5-Fu
- Where
- China
- Volunteers
- 234 people
- Sponsor
- Peking University
Triple Negative Breast Cancer, Breast Cancer
TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature
The purpose of this study is to compare the efficacy and safety between docetaxel combined with doxorubicin (epirubicin) and cyclophosphamide followed by gemcitabine combined with cisplatin and doxorubicin (epirubicin) combined…
- Trial name
- NCT02641847
- Testing
- docetaxel, doxorubicin or epirubicin, cyclophosphamide
- Where
- China
- Volunteers
- 503 people
- Sponsor
- Fudan University
Breast Cancer
Mathematical Modeling to Predict Response to Neoadjuvant Chemotherapy in Breast Cancer
This is a feasibility study evaluating the use of a mathematical model to predict response to standard neoadjuvant anthracycline / taxane based chemotherapy in patients with breast cancer.
- Trial name
- NCT03983538
- Testing
- Mathematical modeling to predict response to chemotherapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- New Mexico Cancer Research Alliance
Carcinoma of Unknown Primary
Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of Origin
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective for metastatic cancer of an…
- Trial name
- NCT00022178
- Testing
- cisplatin, cyclophosphamide, doxorubicin hydrochloride
- Where
- United Kingdom
- Sponsor
- The Christie NHS Foundation Trust
Intravascular Large B-Cell Lymphoma
Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma
This is a prospective single-arm phase II study, and the purpose of this study is to evaluate the efficiency of zanubrutinib combined with R-CHOP regimen in newly diagnosed primary intraocular lymphoma.
- Trial name
- NCT04899570
- Testing
- Zanubrutinib, Rituximab, Cyclophosphamide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Recurrence Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma
Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma
Objectives: The purpose of this study is to evaluate the safety and efficacy of dendritic cell-precision multiple antigen T cells with transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma.
- Trial name
- NCT02638857
- Testing
- TACE, Dendritic Cell, lipiodol
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Second Military Medical University
Breast Cancer
Investigating the Biological Effects of the Addition of Zoledronic Acid to Pre-operative Chemotherapy in Breast Cancer
There is clear preclinical in vitro and in vivo evidence of sequence dependent synergy between chemotherapy agents and zoledronic acid.
- Trial name
- ANZAC (NCT00525759)
- Testing
- 5-FU, Epirubicin, Cyclophosphamide, Docetaxel, 5-FU, Epirubicin, Cyclophosphamide, Docetaxel, Zoledronic acid
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Breast Cancer
Study of the Effect of Glutamine Supplementation on Chemotherapy Induced Toxicities in Breast Cancer Patients
Glutamine, a non essential branched chain amino acid, is most important non toxic nitrogen carrier in body. It participates in variety of physiological functions.
- Trial name
- NCT00772824
- Testing
- Glutamine, IV Glutamine
- Where
- India
- Volunteers
- 23 people
- Sponsor
- Banaras Hindu University
Diffuse Large B-cell Lymphoma
The Study of Pegylated Liposomal Doxorubicin Contrast Epirubicin for the Treatment of Diffuse Large B-cell Lymphoma
270 untreated patients, age between 18 and 65 years , with diffuse large B-cell lymphoma (B-DLCL) were treated with a pegylated liposomal doxorubicin (PL-doxorubicin) modified CHOP-rituximab regimen.
- Trial name
- NCT03022123
- Testing
- PL-doxorubicin and epirubicin
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Hebei Medical University Fourth Hospital
Triple Negative Breast Cancer
Albumin-Bound Paclitaxel Followed by Epirubicin in Combination With Cyclophosphamide in Triple Negative Breast Cancer
This is an open-label, single arm, two-stage Simon Design study for women with Triple Negative Breast Cancer treated with Nanoparticle Albumin-Bound Paclitaxel and Carboplatin.
- Trial name
- NCT03799679
- Testing
- Chemotherapeutic Agent
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Lymphoma, B-Cell
R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL
In this study，lenalidomide was added in the first-line treatment in the newly diagnosed highly invasively non-Hodgkin B-cell lymphoma. The R2-CHOP/R2-EPOCH etc was applied compared with the classical R-CHOP/R-EPOCH etc.
- Trial name
- NCT04152577
- Testing
- R2-combination chemotherapy, R-combination chemotherapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shandong Provincial Hospital
Gastric Cancer
Randomized Phase III Trial of Adjuvant Chemotherapy or Chemoradiotherapy in Resectable Gastric Cancer (CRITICS)
The purpose of this study is to evaluate the efficacy and safety of combined chemotherapy and radiotherapy (in comparison to chemotherapy alone) as adjuvant treatment after surgery for gastric cancer.
- Trial name
- NCT00407186
- Testing
- cisplatin+capecitabine, radiotherapy, epirubicin+cisplatin+capecitabine
- Where
- Netherlands
- Volunteers
- 788 people
- Sponsor
- Dutch Colorectal Cancer Group
Breast Cancer
Immunomonitoring of Breast Cancer Patients During Systemic Treatment
This study aims to constitute a most complete biological collection for patients treated for localized or metastatic breast cancer (in different cohorts depending on the type of systemic treatment received), in order to describe…
- Trial name
- IMMUNE CAPTURE (NCT04925856)
- Testing
- blood sample
- Where
- 2 sites in France
- Volunteers
- 150 people
- Sponsor
- Centre Georges Francois Leclerc
Malignant Mesothelioma
Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00017186
- Testing
- epirubicin hydrochloride, gemcitabine hydrochloride
- Where
- 24 sites in United States
- Volunteers
- 69 people
- Sponsor
- Alliance for Clinical Trials in Oncology